Fresenius Kabi
Focus: Fresenius Kabi is a German specialty pharma company focused on infusion therapy and critical care, with 5,000+ employees and a strong position in nephrology and oncology markets.
Profile data last refreshed 44m ago · AI intelligence enriched 2w ago
Employees
5000+
Open Jobs
105+116 this month
Hot — 200 jobs added in 30d
Net +116 (200 new, 84 removed). Aggressive expansion phase.
Should You Work at Fresenius Kabi?
AI assessmentBest for commercial, operations, and manufacturing professionals seeking stability in a specialty pharma context; less ideal for R&D-focused careers due to weak pipeline and innovation velocity.
Why Work Here
- Established market leader in nephrology and infusion therapy with peak-stage blockbuster (VELPHORO generating $466M Part D spend)
Data completeness
5/9 — Partial
Company HealthWatch
Pipeline
Early-stage
50 total
LOE Risk
2 imminent
NAROPIN
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$466M Part DStable
Peak9.0yr
Flagship product representing 72% of company revenue; patent protection until 2035 provides multi-year runway but creates dangerous concentration risk.
Help build intelligence for Fresenius Kabi
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.